INTRODUCTION
============

Among the antiviral agents available for treatment-naïve chronic hepatitis B (CHB) patients, entecavir (ETV) and tenofovir (TDF) exhibit potent antiviral effects and low resistance rates.[@B1][@B2][@B3] Telbivudine (LdT) also deserves consideration as an initial antiviral agent due to its relatively strong antiviral effect and reports of efficacy when used as an initial treatment for appropriate patient groups based on the roadmap treatment concept.[@B4][@B5] However, LdT is currently not recommended as a first-line drug because of concern over possible treatment failure in patients with a suboptimal response and the higher resistance compared to ETV and TDF.[@B6] Nonetheless, LdT has several advantages including its cost and usability in clinical practice. According to a recent report,[@B7][@B8][@B9] in patients with a suboptimal response to LdT or adefovir (ADV), rescue therapy with ETV produced a high complete virologic response (CVR) rate. Among those who did not respond to a nucleos(t)ide analogue (NA) or who had mutant resistance to LdT, the efficacy of TDF rescue therapy was outstanding.[@B10][@B11][@B12][@B13][@B14][@B15][@B16][@B17] Thus, these studies suggest that, when the effects of initial treatment with LdT are insufficient, treatment with a rescue antiviral agent may be successful. However, in patients with CHB treated with LdT, little is known about the treatment modification rates or long-term outcomes in real world experience.

Therefore, in this 3-year retrospective study, we analyzed the virologic and biochemical responses in patients initially treated with LdT, including those who were maintained on the initial LdT treatment and those who required treatment modification for various reasons. The responses of these patients and those in an ETV initial treatment group were compared.

MATERIALS AND METHODS
=====================

Patients
--------

In this retrospective study, the data from 131 antiviral-treatment-naïve Korean CHB patients who started antiviral therapy with 0.5 mg ETV or 600 mg LdT between February 2007 and June 2012 in the National Health Insurance Service Ilsan Hospital were analyzed. Patients with electronic medical records who charted a 3-year clinical course of their disease and its treatment were included. Patients who previously received an oral NA or interferon, those with co-infection by hepatitis C virus, hepatitis D virus, or human immunodeficiency virus, and those with decompensated liver cirrhosis were excluded. The antiviral agent was selected according to the physician\'s discretion and patient\'s preference. Baseline patient data, including age, gender, medical history, hepatitis B virus (HBV) DNA level, aspartate aminotransferase (AST), and alanine aminotransferase (ALT), were evaluated. Patients were followed up every 3 months for clinical assessments including compliance, adverse effects of the NA, and serum levels of HBV DNA, AST, and ALT. Treatment modification occurrence, type of treatment modification (switch to another NA, addition of another NA, or dose modification), reason for treatment modification \[partial virologic response (PVR), viral resistance, and adverse event induced by the NA\], CVR occurrence, and ALT normalization were investigated.

Study endpoints
---------------

The primary endpoints were a CVR at 3 years and cumulative incidence of a CVR during 3 years of treatment. Secondary endpoints were treatment maintenance at 3 years, types of and reasons for treatment modification, rate of ALT normalization, and the cumulative incidence of a CVR to rescue antiviral therapy.

Definition
----------

A CVR was defined as a decrease in serum HBV DNA to \<20 IU/mL, and a PVR defined as a decrease in HBV DNA \>1 log~10~ IU/mL but still detectable HBV DNA after 6 months of antiviral therapy. ALT normalization was defined as a decrease in serum ALT to \<40 IU/L. Viral breakthrough was defined as an HBV DNA increase \>1 log~10~ IU/mL from the nadir level during antiviral treatment and confirmation of a resistance mutation by genetic analysis. Treatment maintenance was defined as the maintenance of initial antiviral agent for 3 years without treatment modification, and treatment modification was defined as a change in treatment including a switch to or the addition of another antiviral agent.

Statistical analysis
--------------------

Continuous data were analyzed with Student\'s t-test and are presented as mean±standard deviation or as a proportion. Categorical variables were analyzed in a chi-square test or with Fisher\'s exact test. The tests were used to identify differences between the ETV and LdT groups in the CVR and treatment maintenance rates at 3 years. The cumulative incidence of a CVR during 3 years of treatment, ALT normalization during 3 years of treatment, and a CVR after rescue therapy were assessed using Kaplan-Meier method. The difference between cumulative curves was evaluated using the log-rank test. A *p* value \<0.05 was considered statistically significant. All of the statistical analyses were performed using SPSS version 22.0 (IBM Corp., Armonk, NY, USA). Approval for our study, including research conducted within the database, was obtained from the Ethics Committee of National Health Insurance Ilsan Hospital (IRB No. 2015-02-001).

RESULTS
=======

Patient characteristics
-----------------------

Among the 131 patients enrolled in the study, 84 were treated with ETV and 47 with LdT ([Fig. 1](#F1){ref-type="fig"}). The baseline characteristics of the patients are shown in [Table 1](#T1){ref-type="table"}. The mean age was 47.0±10.6 years in the ETV group and 50.4±11.4 years in the LdT group (*p*=0.086). The proportion of males in the two groups was 63.4% and 61.7%, respectively; the difference was not significant (*p*=0.982). There were also no statistically significant differences in age, gender, liver cirrhosis, initial serum AST, initial serum ALT, and initial serum total bilirubin between the ETV and LdT groups. However, patients in the ETV group had higher serum HBV DNA levels than those in the LdT group (7.10±1.27 log~10~ IU/mL vs. 5.92±1.91 log~10~ IU/mL, *p*\<0.001) and higher proportion of hepatitis B e antigen (HBeAg) positive patients than those in the LdT group (100% vs. 53.2%, *p*\<0.001).

Rate of treatment maintenance and types of and reasons for treatment modification
---------------------------------------------------------------------------------

Patients in the ETV group had a significantly higher rate of treatment maintenance during 3 years of the study than patients in the LdT group (97.6% vs. 40.4%, *p*\<0.001).

Treatment modification was required in 30 (22.9%) patients: only 2 (2.4%) in the ETV group, but 28 (59.4%) in the LdT group. In the ETV group, treatment modification consisted of a switch to another NA for both patients. The patient with a PVR was switched to TDF, and the patient with viral resistance was switched first to ADV and lamivudine combination therapy, and then to TDF. In the LdT group, a switch to another NA was required in 26 (92.9%) patients, and NA was added in 2 (7.1%) other patients ([Table 2](#T2){ref-type="table"}). In the LdT group, the reasons for treatment modification were a PVR in 14 patients, resistance in 10 patients, and an adverse event in 4 patients ([Fig. 1](#F1){ref-type="fig"}). Among the 10 patients with resistance, 8 had M204I mutations and 2 had L80I and M204I mutation. The specific types of drug switches and additions are summarized in [Table 2](#T2){ref-type="table"}.

Virologic and biochemical responses during treatment
----------------------------------------------------

In the ETV and LdT groups, 75 of 84 (89.3%) and 45 of 47 (95.7%) patients, respectively, including those who required treatment modification, demonstrated a CVR at the year 3. The difference between the two groups was not significant (odds ratio=0.370, *p*=0.326). The cumulative incidence rate of a CVR was also not significantly different (*p*=0.986) ([Fig. 2A](#F2){ref-type="fig"}). The ETV and LdT groups did not differ in their biochemical responses, as demonstrated by the cumulative incidence rate of ALT normalization (*p*=0.178) ([Fig. 2B](#F2){ref-type="fig"}).

Complete virologic response in patients with treatment modification
-------------------------------------------------------------------

In the ETV group, two patients switched from ETV to another antiviral agent ([Table 2](#T2){ref-type="table"}). In both patients, the switch was implemented 30 months after ETV initiation, but a CVR was not achieved until 3 years after the initiation. In the LdT group, 14 patients required treatment modification due to a PVR ([Fig. 1](#F1){ref-type="fig"}). Three of these patients were switched to TDF, and all of them achieved a CVR. A total out of 9 of 14 patients were switched to ETV, 8 of whom achieved a CVR. In 2 of the 14 patients, two drug switches were necessary (LdT→ETV→TDF). Both of the patients were treated with ETV for 12 months but were switched back to TDF because of a PVR. One of the patients had a CVR 16 months after switching to TDF, and the other patient had a CVR at 3 months.

Ten patients in the LdT group required treatment modification due to resistance. Two of these patients were switched to ADV monotherapy or combination therapy; one of these patients achieved a CVR. Eight of ten patients were switched to TDF monotherapy or combination therapy, and all of them achieved a CVR. In the LdT group, 4 patients required treatment modification due to an adverse event (2 with myopathy and 2 with abdominal pain). After a switch to ETV, all of them achieved a CVR. A comparison of the virologic response to ETV and TDF as rescue therapies showed that all 15 patients who received TDF rescue therapy and 10 of 13 patients who received ETV rescue therapy achieved a CVR ([Table 3](#T3){ref-type="table"}). The cumulative CVR incidence following rescue therapy was significantly higher in the TDF group than in the ETV group (*p*=0.009) ([Fig. 3](#F3){ref-type="fig"}).

DISCUSSION
==========

A favorable outcome was expected with LdT treatment because of its relatively strong antiviral effect. It is particularly effective for patients with a low baseline HBV DNA level (HBeAg-positive patients with baseline HBV DNA \<9 log~10~ copies/mL, HBeAg-negative patients with baseline HBV DNA \<7 log~10~ copies/mL, and ALT \>2×upper limit of normal).[@B5] Therefore, long-term treatment with LdT should be considered in appropriate patients. In fact, a recent meta-analysis that compared the efficacy of ETV with that of LdT reported similar virologic and biochemical responses with the two drugs.[@B5][@B18][@B19]

However, LdT is not recommended as a first-line antiviral agent for CHB because of relatively high risks of treatment failure due to resistance and a PVR. Instead, ETV and TDF are currently recommended as first-line antiviral agents for CHB, based on their outstanding antiviral effects and very low rates of resistance despite long-term use. ETV and TDF have also been evaluated as rescue therapies. In a recent study,[@B7] rescue therapy with ETV resulted in a CVR in 80% of patients who had a PVR to LdT; for patients who did not respond to a NA, rescue therapy with TDF resulted in a CVR in 90%.[@B10] Some studies have also shown that, TDF, when used as a rescue therapy, has excellent antiviral activity in most patients who develop antiviral resistance to LdT.[@B11][@B12][@B13][@B14][@B15][@B16][@B17] However, little is known about treatment modification rates and long-term outcomes after treatment modification in patients with CHB treated with LdT in real world experience.

In the present study, we compared the virologic and biochemical responses (including after treatment modification) obtained in patients treated with LdT versus ETV as the first-line antiviral agent during a 3-year period. The initial treatment maintenance rate at 3 years was significantly higher in the ETV than in the LdT group (97.6% vs. 40.7%), similar to the results reported by Chien, et al.[@B6]

In the ETV group, most patients maintained their initial antiviral agent during the 3-year treatment period, whereas, there was a relatively high rate of treatment modification in the LdT group because of a partial response, resistance, or adverse reaction. However, an analysis of data, including a CVR after treatment modification, failed to show a significant difference between the two groups during the 3 years in the CVR rate, the cumulative incidence of a CVR, or the cumulative incidence of ALT normalization. This could be attributed to the effects of the rescue antiviral agent. Roughly 90% of the study patients who failed to show a complete response to a first-line antiviral agent achieved a CVR after switching to a rescue antiviral agent. It is thus possible that a CVR can be obtained following effective treatment modification.

On the other hand, a comparison of the efficacy of TDF and ETV as rescue therapies revealed that 100% of patients who received TDF achieved a CVR, compared to 77% of patients treated with ETV. For all of the patients who had a PVR to ETV rescue therapy, TDF rescue therapy yielded a CVR, which demonstrated greater efficacy of TDF than ETV as a rescue antiviral agent, as reported in a recent study.[@B7][@B20][@B21] We were unable to assess the factors affecting the efficacy of ETV or TDF rescue therapy. However, these results were based on small-scale retrospective data. To compare ETV and TDF as a rescue therapy, clinical study with high quality of evidence is needed.

There are a few limitations to our study. First, because this study was conducted at a single center, the number of study patients was small; in addition, considering the nature of CHB treatment, a 3-year period is insufficient to fully determine the efficacy of an antiviral agent. Multicenter randomized controlled study is needed to confirm the efficacy of LdT therapy with treatment modification, but it is difficult in Korea. Second, many patients did not complete the 3-year follow-up, a shortcoming of the retrospective design of the study patients treated in real clinical practice. Finally, for a statistically valid comparison of the efficacy of rescue antiviral agents and a determination of the factors related to their efficacy, the number of cases was too small.

Nonetheless, our results showed significantly superior maintenance rate of ETV compared to LdT, although there were no differences in virologic or biochemical response at 3 years between patients initially treated with either drug, after rescue treatment modification. Therefore, LdT merits consideration as a first-line antiviral agent for CHB. When initial LdT treatment fails, TDF may be a more effective rescue antiviral agent than ETV.
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###### Baseline Characteristics of Patients with Chronic Hepatitis B

![](ymj-59-383-i001)

  Variables                       ETV (n=84)    LdT (n=47)    *p* value
  ------------------------------- ------------- ------------- -----------
  Age (yr)                        47.0±10.6     50.4±11.4     0.086
  Male sex, n (%)                 52 (63.4)     29 (61.7)     0.982
  HBeAg positive, n (%)           84 (100)      25 (53.2)     \<0.001
  Liver cirrhosis, n (%)          23 (27.4)     17 (36.2)     0.295
  HBV DNA (log~10~ IU/mL)         7.10±1.27     5.92±1.91     \<0.001
  Serum total bilirubin (mg/dL)   1.53±1.71     1.28±1.52     0.412
  Serum AST (IU/L)                175.5±254.0   102.8±129.7   0.070
  Serum ALT (IU/L)                217.2±320.7   119.4±175.7   0.055

HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ETV, entecavir; LdT, telbivudine.

###### Treatment Modification in Patients with Chronic Hepatitis B Treated in a 3-Year Period

![](ymj-59-383-i002)

  Variables                                  Total (n=30)   ETV (n=2)   LdT (n=28)
  ------------------------------------------ -------------- ----------- ------------
  Type of treatment modification, n (%)                                 
   Switch to another NA                      28 (93.3)      2 (100)     26 (92.9)
    ETV → TDF                                1 (3.3)        1 (50)      0
    ETV → ADV+LAM → TDF                      1 (3.3)        1 (50)      0
    LdT → TDF                                7 (23.3)       0           7 (25)
    LdT → ETV                                13 (43.3)      0           13 (46.4)
    LdT → ETV → TDF                          2 (6.7)        0           2 (7.1)
    LdT → ADV                                1 (3.3)        0           1 (3.6)
    LdT → ADV+LAM                            1 (3.3)        0           1 (3.6)
    LdT → ADV → LAM+TDF                      1 (3.3)        0           1 (3.6)
    LdT → ADV+LAM → TDF                      1 (3.3)        0           1 (3.6)
   Addition of another NA                    2 (6.7)        0           2 (7.1)
    LdT+TDF                                  2 (6.7)        0           2 (7.1)
  Reason for treatment modification, n (%)                              
   Partial virologic response                15 (50)        1 (50)      14 (50)
   Resistance                                11 (36.7)      1 (50)      10 (35.7)
   Adverse event                             4 (13.3)       0           4 (14.3)

NA, nucleos(t)ide analogue; ETV, entecavir; TDF, tenofovir; ADV, adefovir; LAM, lamivudine; LdT, telbivudine.

###### Comparison of Patients Treated with ETV and TDF after Initial Telbivudine Treatment at Treatment Modification
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  Variables                       ETV (n=13)   TDF (n=15)    *p* value
  ------------------------------- ------------ ------------- -----------
  Age (yr)                        47.2±13.3    54.1±9.7      0.121
  Male sex, n (%)                 6 (46.2)     6 (85.7)      0.158
  HBeAg positive, n (%)           10 (76.9)    3 (42.9)      0.174
  Liver cirrhosis, n (%)          5 (38.5)     3 (42.9)      1.000
  HBV DNA (log~10~ IU/mL)         6.63±1.71    5.91±1.72     0.283
  Serum total bilirubin (mg/dL)   1.02±0.24    1.74±2.63     0.333
  Serum AST (IU/L)                78.3±59.0    123.1±165.7   0.365
  Serum ALT (IU/L)                103.8±97.0   143.1±226.7   0.568

HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ETV, entecavir; TDF, tenofovir.

[^1]: ^\*^Jong Won Choi and Se Hyun Kim contributed equally to this work.
